884 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Purchased by MQS Management LLC

MQS Management LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 884 shares of the biotechnology company's stock, valued at approximately $273,000.

Other institutional investors have also recently made changes to their positions in the company. Reyes Financial Architecture Inc. grew its stake in shares of United Therapeutics by 35.4% in the first quarter. Reyes Financial Architecture Inc. now owns 428 shares of the biotechnology company's stock worth $132,000 after acquiring an additional 112 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of United Therapeutics by 0.8% in the first quarter. Louisiana State Employees Retirement System now owns 12,500 shares of the biotechnology company's stock worth $3,853,000 after acquiring an additional 100 shares during the period. Xponance Inc. grew its stake in shares of United Therapeutics by 0.9% in the first quarter. Xponance Inc. now owns 7,417 shares of the biotechnology company's stock worth $2,286,000 after acquiring an additional 67 shares during the period. Weil Company Inc. grew its stake in shares of United Therapeutics by 259.3% in the first quarter. Weil Company Inc. now owns 4,570 shares of the biotechnology company's stock worth $1,409,000 after acquiring an additional 3,298 shares during the period. Finally, State of Michigan Retirement System grew its stake in shares of United Therapeutics by 1.6% in the first quarter. State of Michigan Retirement System now owns 12,432 shares of the biotechnology company's stock worth $3,832,000 after acquiring an additional 200 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

UTHR has been the subject of several recent research reports. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price for the company. JPMorgan Chase & Co. dropped their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Bank of America dropped their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $383.08.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the transaction, the director owned 19,384 shares in the company, valued at $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at $1,416,021.17. This trade represents a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,681 shares of company stock valued at $22,140,089 over the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Stock Down 1.5%

United Therapeutics stock traded down $4.44 during mid-day trading on Friday, reaching $292.89. 149,141 shares of the company's stock traded hands, compared to its average volume of 441,778. The company has a market cap of $13.21 billion, a price-to-earnings ratio of 11.69, a PEG ratio of 6.52 and a beta of 0.53. The stock has a 50 day moving average of $300.61 and a two-hundred day moving average of $318.55. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. United Therapeutics's revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.17 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.